Q7 Multicell Technology Inc management needs to be replaced/removed.
MCET just stopped paying for the website:
On Thu, Sep 10, 2020, 2:51 PM Barbara Corbett <mcetinvestor@aol.com> wrote:
Hi,
Hope all is well with you!
Sorry, I do not know why we no longer have a web site. There are other companies named MultiCell.
Mr. Newmin and I are both now retired, in spite of still being listed in the Yahoo Finance profile.
Mr. Ed Sigmond is now running the company. Perhaps he can update that and answer some questions for you.
Barbara Corbett.
Barbara,
Thank you again for keeping in touch.
No, I haven't heard back from Mr. Sigmond yet.
To be honest, I am not sure I will or how this whole MCET stock works at this point?
Personally, since you and Mr Newmin know more about MCET then anyone else. I would be on a mission if I was you? That's if you still own this stock? If not, I hope you are enjoying your personal life?
My first thought is to gather everything you have on Fa2N-4. And any other patent that might be used by someone today.
Call whom ever wrote the contract/agreement with MCET and Xeno Tech.
Call the Patent attorney that filed Fa2N-4 in the first place.
Be prepared that they don't the records anymore. Hopefully they have it at least on microfilm?
As you know Patents last twenty years.
Ask them what the options are and why did you pay all that money to them if they don't want to help? Then ask them for their help again.
Just because the contract is terminated with Xeno Tech, they don't have the right to sell this line or does anyone have right to use this line either. And Sekisui Xeno Tech sure don't have the right to have a license it to anyone. This to me is against the law.
I would reach out to everyone that might be now or in the future that is selling any line remotely close to your line.
Barbara, with yours and Mr Newmin's knowledge regarding this line. You can pretend that you're in the market to use this line, or you want to have them develop your drug. Anything goes. Am sure you and a attorney can come up with something to nail them. Then maybe asked them later I heard they don't have a patent on Fa2N-4. And see what they say.
Where am from, Michigan and Ohio we can record a conversation if one party knows it's getting recorded.
I just read Florida is a two party state. Meaning both people needs to know your conversation is getting recorded. I would go somewhere you can record everything if your attorney thinks that would help?
Am hope you have an idea of all the players might be?
I would get as much information as you can from all of them. Everything possible.
Then decide what the next step is, if any?
I guess, also keep this as quite as possible until your ready to drop the bomb. Then make it go viral, let everyone that has a contract them them, what happened and lawsuits are pending.
As you know a judge can award up to 3 times what a jury awards.
Don't let them be in the driver's seat.
I would consider hiring a patent troll attorney. There are companies that come up with Patents just waiting for a company to infringe on their patent. With no intention themselves are using it it's just to sue them.
Mr. Newmin won that lawsuit in 2018. That could be a good down payment for a attorney?
Companies aren't sueing as much anymore for drug infringement. But If you can, I wouldn't hesitate.
You can't use the $250,000 you have in stock from 2018 anyways.
Well, for what it's worth, that's what I think.
On Mon, Sep 21, 2020, 4:33 PM Barbara Corbett <mcetinvestor@aol.com> wrote:
Hi, again,
I am re-reviewing our correspondence and wondering if you heard back from Mr. Sigmond.
I got no email from him.
Belated condolences for your mother's passing.
I see no record of having gotten a twitter message from anyone re MultiCell. I use Twitter only to promote my art/photography.
The MultiCell -Xeno Tech agreement was terminated. I don't know what we can do about them continuing to sell our patented cells.
"MultiCell Takes Control of Cell Marketing Program
Monday February 6, 6:30 am ET PROVIDENCE, R.I.--(BUSINESS WIRE)--Feb. 6, 2006--MultiCell Technologies, Inc. (OTCBB:MCET - News), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, and a leading supplier of non-tumorigenic immortalized human hepatocytes, announced today it had terminated the exclusive license agreement with XenoTech, LLC of Lenexa, Kansas, effective January 31, 2006, for failure to meet minimum royalty obligations.
Under terms of the 2003 agreement, XenoTech was allowed to sell sub-licenses for the propagation of Multicell's immortalized human liver cells ("hepatocytes"). These cells may be used to develop highly predictive, high-throughput drug development assays for drug discovery, lead optimization and pharmacogenomic studies. Industry statistics show, on the average, it now costs almost $1 billion to develop a new drug. Many drugs fail in development because the human liver cannot process toxic aspects of many new drug candidates. MultiCell believes that highly predictive assays such as ones using its hepatocytes could predict potential failures earlier in the development process thus saving pharmaceutical companies millions of dollars in drug development costs. "We believe our immortalized human hepatocytes are ideal products, which help to fill a currently unmet need within the pharmaceutical industry, and that there are no other consistent products available to pharmaceutical companies for predicting the liver toxicity of new drug compounds," Stephen Chang, Ph.D., President of Multicell explained. "We believe that one of MultiCell's greatest strategic advantages is our management team's ability to move quickly to complete transactions as evidenced in the past six months. We plan to take advantage of this strength by taking direct control of the marketing and selling activities for this key product."
About MultiCell Technologies, Inc.MultiCell Technologies, Inc. is a developer of therapeutic products, and a supplier of immortalized human cell lines for drug discovery applications. With its majority-owned subsidiary MultiCell Immunotherapeutics, Inc., MultiCell is working to commercialize new therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases. MultiCell's cellular systems research labs are in Lincoln, RI. MultiCell Immunotherapeutics is located in San Diego, CA.
For more information about MultiCell see multicelltech.com. Information on our website is not part of this press release.
Caution Regarding Forward-Looking StatementsAny statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe", "will", "expect", "anticipate", "estimate", "intend", "plan", "forecast", "could", and "would". Examples of such forward looking statements include statements regarding contemplated guidance in the investment and financial markets, evaluation of the company's lead drug candidates, or commencement of clinical trials. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2004, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events."
That's all for now.
Best regards
Barbara Corbett
News 
Market Data 
Discover 
